Skip to main content

Advertisement

SpringerLink
Log in

The long-term outcome of anti-Jo-1-positive inflammatory myopathies

  • ORIGINAL COMMUNICATION
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract.

Objective:

To determine the response to treatment and the long-term outcome of patients with the antisynthetase syndrome associated with anti-Jo-1-antibodies.

Patients and Methods:

A total of 12 patients with histologically proven myositis and anti-Jo-1-autoantibodies were evaluated over a mean follow-up period of 66.4 months. In all patients neuromuscular function tests, electromyographic examinations, pulmonary function tests and high-resolution-computed tomography of the lungs were performed regularly.

Results:

Muscle function improved in all patients with treatment, and a complete clinical response was achieved in 5 patients. Pulmonary function worsened in 1 patient, who died from respiratory failure, but normalised in 4 patients. Arthropathy progressed despite improvement of myositis and pulmonary status in 2 patients. Discontinuation of treatment was facilitated in 1 patient, although long-term therapy was required in 10 patients. In 2 patients with refractory disease, treatment with intravenous immunoglobulins was successful. Severe side effects of treatment occurred in 7 patients and overall mortality rate was one of 12 (8 %).

Conclusion:

The antisynthetase syndrome associated with anti-Jo-1-antibodies requires long-term immunosuppressive therapy in most patients. Whereas a complete clinical response of muscular symptoms is frequent, continued deterioration of the pulmonary system may occur despite immunosuppressive treatment, and may lead to fatal outcome. An interdisciplinary therapeutic approach is necessary for best possible results in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Angelini C, Menegazzo E, Fanin M (1993) Multifactorial study of inflammatory myopathies. Report of 29 cases. Ital J Neurol Sci 14:69–76

    CAS  PubMed  Google Scholar 

  2. Arnett FC, Whelton JC, Zizic TM, Stevens MB (1973) Methotrexate therapy in polymyositis. Ann Rheum Dis 32:536–546

    CAS  PubMed  Google Scholar 

  3. Arnett FC, Hirsch TJ, Bias WB, Nishikai M, Reichlin M (1981) The Jo-1 antibody system in myositis: relationships to clinical features and HLA. J Rheumatol 8:925–930

    CAS  PubMed  Google Scholar 

  4. Arsura EL, Greenberg AS (1988) Adverse impact of interstitial pulmonary fibrosis on prognosis in polymyositis and dermatomyositis. Semin Arthritis Rheum 18:29–37

    Article  CAS  PubMed  Google Scholar 

  5. Cherin P, Herson S, Wechsler B, Piette JC, Bletry O, Coutellier A, Ziza JM, Godeau P (1991) Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 91:162–168

    Article  CAS  PubMed  Google Scholar 

  6. Clarke AE, Bloch DA, Medsger TA Jr, Oddis CV (1995) A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 38:1218–1224

    CAS  PubMed  Google Scholar 

  7. Cronin ME, Miller FW, Hicks JE, Dalakas M, Plotz PH (1989) The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy. J Rheumatol 16:1225–1228

    CAS  PubMed  Google Scholar 

  8. Dalakas MC (1998) Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 51:S37–45

    CAS  PubMed  Google Scholar 

  9. Fischer E, Thiele A, Stierle HE, Lang B (1995) Anti-Jo-1-Antikörper: Spezifische Autoantikörper für Polymyositis mit interstitieller Lungenfibrose. 2 Fallvorstellungen [Anti-Jo-1 antibodies: specific autoantibodies for polymyositis with interstitial pulmonary fibrosis. 2 case reports]. Z Rheumatol 54:171–177

    CAS  PubMed  Google Scholar 

  10. Gruhn WB, Diaz-Buxo JA (1987) Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis. J Rheumatol 14:1045–1047

    CAS  PubMed  Google Scholar 

  11. Haga HJ, D’Cruz D, Asherson R, Hughes GR (1992) Short term effects of intravenous pulses of cyclophosphamide in the treatment of connective tissue disease crisis. Ann Rheum Dis 51:885–888

    CAS  PubMed  Google Scholar 

  12. Hirakata M, Nagai S (2000) Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol 12:501–508

    Article  CAS  PubMed  Google Scholar 

  13. Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, Plotz PH, Miller FW (1993) Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med 94:379–387

    Article  CAS  PubMed  Google Scholar 

  14. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine 70:360–374

    CAS  PubMed  Google Scholar 

  15. Maeda K, Kimura R, Komuta K, Igarashi T (1997) Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? Scand J Rheumatol 26:24–29

    CAS  PubMed  Google Scholar 

  16. Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ (1990) Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med 77:1019–1038

    CAS  PubMed  Google Scholar 

  17. Mitsunaka H, Tokuda M, Hiraishi T, Dobashi H, Takahara J (2000) Combined use of cyclosporine A and methotrexate in refractory polymyositis. Scand J Rheumatol 29:192–194

    Article  CAS  PubMed  Google Scholar 

  18. Oddis CV (2000) Current approach to the treatment of polymyositis and dermatomyositis. Curr Opin Rheumatol 12:492–497

    Article  CAS  PubMed  Google Scholar 

  19. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE (1999) Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet 353:1762–1763

    Article  CAS  PubMed  Google Scholar 

  20. Phillips BA, Zilko P, Garlepp MJ, Mastaglia FL (1998) Frequency of relapses in patients with polymyositis and dermatomyositis. Muscle Nerve 21:1668–1672

    Article  CAS  PubMed  Google Scholar 

  21. Targoff IN (2000) Update on myositisspecific and myositis-associated autoantibodies. Curr Opin Rheumatol 12:475–481

    Article  CAS  PubMed  Google Scholar 

  22. Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, Nemcova D, Charvat F (2000) Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 29:95–102

    Article  CAS  PubMed  Google Scholar 

  23. Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, Thornton BC, Burgess SH, Plotz PH, Miller FW (1998) Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum 41:392–399

    Article  CAS  PubMed  Google Scholar 

  24. Yoshida T, Koga H, Saitoh F, Sakamoto M,Harada M, Yoshida H, Sakisaka S, Sata M (1999) Pulse intravenous cyclophosphamide treatment for steroidresistant interstitial pneumonitis associated with polymyositis. Intern Med 38:733–738

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Friedrich-Baur-Institut, Department of Neurology, University of Munich, Ziemssenstr. 1a, 80336, München, Germany

    Michael Späth,  Mira Schröder,  Beate Schlotter-Weigel,  Maggie C. Walter,  Dieter Pongratz &  Wolfgang Müller-Felber

  2. Department of Internal Medicine, University of Munich, Ziemssenstr. 1a, 80336, München, Germany

    Hubert Hautmann

  3. Department of Radiology, University of Munich, Ziemssenstr. 1a, 80336, München, Germany

    Gerda Leinsinger

Authors
  1. Michael Späth
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mira Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Beate Schlotter-Weigel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maggie C. Walter
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hubert Hautmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gerda Leinsinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Dieter Pongratz
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wolfgang Müller-Felber
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Müller-Felber.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Späth, M., Schröder, M., Schlotter-Weigel, B. et al. The long-term outcome of anti-Jo-1-positive inflammatory myopathies. J Neurol 251, 859–864 (2004). https://doi.org/10.1007/s00415-004-0449-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-0449-5

Key words

Search

Navigation